Camille Graham, MD
Otolaryngology · Greenville, TXNPI 1720003569
Payments from drug & device makers
Across 128 payments — averaging $55.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$2K
- Aerin Medical Inc.$2K
- Stryker$915
- Acclarent, Inc$659
- Smith+Nephew$457
- Optinose US, Inc.$280
- plus $1K from 17 others
What the payments were for
- Travel & lodging$3,71952%
- Food & beverage$3,41948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 8 | $1,915 |
| Aerin Medical Inc. | 26 | $1,890 |
| Stryker | 13 | $915 |
| Acclarent, Inc | 21 | $659 |
| Smith+Nephew | 3 | $457 |
| Optinose US, Inc. | 24 | $280 |
| Inspire Medical Systems, Inc. | 2 | $189 |
| GSK | 8 | $144 |
| Regeneron Healthcare Solutions, Inc. | 4 | $115 |
| Arrinex, Inc. | 2 | $98 |
| Neurent Medical Limited | 1 | $92 |
| Medtronic | 1 | $80 |
| AstraZeneca | 3 | $66 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| Kaleo, Inc. | 2 | $45 |
| Pharming Healthcare, Inc. | 1 | $29 |
| Alk-abello, Inc | 1 | $27 |
| Integra Lifesciences Corporation | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Novartis | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Intersect ENT, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,139 in reported general payments places this provider in the 80th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 459 | $13,346 |
| Epinephrine | 71 | $11,550 |
| Azelastine Hcl | 217 | $7,404 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,269 |
| SynthroidLevothyroxine Sodium | 78 | $4,601 |
| Montelukast Sodium | 371 | $3,519 |
| Arnuity ElliptaFluticasone Furoate | 15 | $3,108 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 26 | $3,104 |
| Cevimeline Hcl | 19 | $2,810 |
| Fluticasone Propionate | 148 | $2,574 |
| Liothyronine Sodium | 78 | $2,291 |
| Levocetirizine Dihydrochloride | 140 | $2,284 |
| Famotidine | 115 | $2,041 |
| Levothyroxine Sodium | 228 | $1,678 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $15 | $11,55071 claims |
| GSKArnuity Ellipta | $144 | $3,10815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Greenville
- Laurence ChuAustin$37.4M
- Mark ZafereoHouston$7.8M
- Neil GrossHouston$1.5M
- Chad McDuffieFrisco$1.5M
- Ian AlexanderBoerne$999K
- Stephen LaiHouston$968K
- Benjamin CilentoSpring$963K
- Amber LuongHouston$793K
- Jeffrey RosenbloomSan Antonio$720K
- Masayoshi TakashimaHouston$644K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.